UK Office for Life Sciences launches £570m Life Sciences Large Investment Portfolio grant scheme

Mechanism

LSLIP is a large-project subsidy vehicle sitting alongside the UK's broader Life Sciences Sector Plan (part of the UK's Modern Industrial Strategy). It targets a narrow band of very large private capital commitments (GBP 250m+ over three years) rather than SME or early-stage grants — the GBP 130m per-award cap and GBP 570m total pot imply the scheme is designed to land roughly 4-5 flagship investments over its five-year life (Nov 2025-Mar 2030). Eligibility is restricted to UK-registered wholly private-sector businesses in medicines, MedTech, or diagnostics, explicitly excluding academic/NHS bodies. The CMA Subsidy Advice Unit referral (required for subsidies of this scale under the UK Subsidy Control Act 2022) confirms the scheme cleared subsidy- control scrutiny before launch.

Downstream implications

• Positions the UK as a direct grant competitor to EU state-aid life-sciences

packages and to US IRA-adjacent manufacturing incentives for pharma/MedTech capex decisions.

• The GBP 250m minimum-investment threshold means LSLIP targets multinational

pharma/MedTech majors and large biomanufacturing projects, not domestic scale-ups — watch for award announcements naming specific companies/sites.

• Complements existing UK life-sciences grant instruments (e.g. the Local

Innovation Partnerships Fund top-ups filed 2025-10-19) as part of a wider 2025 UK industrial-strategy push in this sector.

Open questions

• No individual award recipients have been named yet; file as an amendment

when the first LSLIP grant recipient is announced.

• Whether LSLIP funding is additive to or displaces existing Life Sciences

Innovative Manufacturing Fund (LSIMF) allocations is not yet clear from public sources.